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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
Toll-like receptor in 
endothelia and acute 
kidney injury
It is now clear that acute renal failure 
is associated with an inflammatory 
response that produces much of the 
interstitial damage seen in this condi-
tion. In this issue, Chen et al. report 
that the expression of Toll-like receptor 
4 (TLR4) in the endothelial cells of the 
vasa rectae was increased after ischemia 
and reperfusion, probably because of 
the production of reactive oxygen spe-
cies seen in this model. Using TLR4 
knockout mice, the authors found the 
expression of the adhesion molecules 
CD54 and CD62E, which in turn can 
attract inflammatory cells to the kidney. 
TLR4 is also expressed in the proximal 
tubule; hence, the inflammation seen in 
acute kidney injury is induced by TLR4 
activation at multiple levels, in endothe-
lia and in epithelia, each contributing 
to local inflammation in the cortex and 
medulla. See page 288.
Effect of bundling on 
erythropoietin use
The introduction of recombinant human 
erythropoietin (rHuEPO) into the treat-
ment of end-stage renal disease (ESRD) 
has revolutionized practice. However, 
as experience increases with its use, a 
number of issues have come to the fore, 
including the proper dose and the tar-
get of hematocrit that provides the most 
benefit with the least side effects. A not-
so-trivial ‘side effect’ is the cost of this 
treatment, quite large considering the 
size of the target population. Hasegawa 
et al. examined the Japanese experience 
before and after the institution of a new 
payment policy for rHuEPO. Before 
2006, each dose was billed separately. 
After that, the Japanese government 
instituted a bundling policy by which 
the erythropoietin was made a part of 
the total ESRD-care bill, producing an 
interesting effect on physician practice. 
While the hematocrit and hemoglobin 
levels before and after the bundling pol-
icy were the same, the use of rHuEPO 
was reduced significantly, by almost 
12%, and the use of intravenous iron was 
increased. See page 340.
Serum HCO3 and 
progression
There is increasing evidence that correct-
ing the acidosis in chronic kidney disease 
reduces the progression of renal failure. 
As they report in this issue, Raphael 
et al. studied a large cohort of patients 
with kidney disease from the African 
American Study of Kidney Disease and 
Hypertension at baseline and durinag 
follow-up. They found that although 
the patients’ mean serum HCO3 of 25 
mmol/l was within the normal range, 
there was a remarkable association 
between reduced risk of death, dialy-
sis, or decreased glomerular filtration 
rate and an increase in serum HCO3. 
Remarkably, the starting serum HCO3 
was normal, and yet the authors observed 
this significant correlation. Whether this 
result was causal or not, of course, will 
need to be determined by a direct test of 
the hypothesis. See page 356.
